A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
详细信息 查看全文
- 作者：Egbert F. Smita ; EF.Smit@vumc.nl" class="auth_mail" title="E-mail the corresponding author ; e.smit@nki.nl" class="auth_mail" title="E-mail the corresponding author ; Yi-Long Wub ; Radj Gervaisc ; Caicun Zhoud ; Enriqueta Felipe ; Jifeng Fengf ; Salih Zeki Guclug ; Mathias Hoiczykh ; Elena Dorokhovai ; Ulrich Freudensprungi ; Susan Grangei ; Pablo Diego Perez-Morenoi ; Lada Mitchelli ; Martin Reckj
- 关键词：Erlotinib ; NSCLC ; Smoking ; Increased dose ; Pharmacokinetics
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：94-101
- 全文大小：1430 K
文摘
- •
CurrentS assessed erlotinib 300 mg/day vs 150 mg/day in current smokers with NSCLC.
- •
Median PFS and OS were 7.0 vs 6.9 weeks and 6.8 months vs 6.8 months (E300 vs E150).
- •
E300 resulted in higher mean erlotinib plasma concentrations vs the E150 dose.
- •
89.2% (E300) and 84.4% (E150) had ≥1 any grade AE (44.3% and 37% had grade ≥3 AEs).
- •
There was no efficacy benefit of a 300 mg dose versus the 150 mg dose in smokers.